Mechanisms of action of ursodeoxycholic acid in cholestatic liver diseases;Mecanisme d'action de l'acide ursodesoxycholique dans les maladies du foie cholestatiques

Gastroenterologie Clinique et Biologique

Volumn 20, Issue 6-7, 1996, Pages 549-559

  Lévy, Stéphane ^a   Capron, Jean Pierre ^b   Erlinger, Serge ^a  

^a BEAUJON HOSPITAL   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

bile acids; cholestasis; liver; treatment; ursodeoxycholic acid

Indexed keywords

BILE ACID; CHENODEOXYCHOLIC ACID; HLA ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; URSODEOXYCHOLIC ACID; CHOLAGOGUE;

BILE ACID METABOLISM; BILE SECRETION; CELL METABOLISM; CELL PROTECTION; DRUG MECHANISM; DRUG STRUCTURE; ENTEROHEPATIC CIRCULATION; HEMODYNAMICS; HUMAN; IMMUNOMODULATION; INTRAHEPATIC CHOLESTASIS; MEMBRANE DAMAGE; ORAL DRUG ADMINISTRATION; REVIEW; SMALL INTESTINE ABSORPTION; CHOLESTASIS; PATHOPHYSIOLOGY; PHYSIOLOGY;

CHOLAGOGUES AND CHOLERETICS; CHOLESTASIS; HUMANS; URSODEOXYCHOLIC ACID;

EID: 0030338678     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. Hagey LR, Crombie DL, Espinoza E, Carey MC, Igimi H, Hofmann AF. Ursodeoxycholic acid in the ursidae: biliary bile acids of bears, pandas and related carnivores. J Lipid Res 1993;34:1911-7.
2. Shoda M. Über die Ursodesoxycholäure aus Barengalle und irhe physiologische Wirking. J Biochem 1927;7:505-17.
3. Bachrach WH, Hofmann AF. Ursodeoxycholic acid in the treatment of cholesterol lithiasis. Dig Dis Sci 1982;24:737-61.
4. May GR, Sutherland LR, Shaffer EA. Efficacy of bile acid therapy for gallstone dissolution: a meta-analysis of randomized trials. Aliment Pharmacol Ther 1993;7:139-48.
5. Ichida F. Clinical experience with ursodeoxycholic acid (S-Urso) for chronic hepatitis. Diagn Treat 1961;36:388.
6. Nakahara T, Yoshida H, Bando T. Effect of Ursosan tablets on chronic hepatic disorders. Diagn Treat 1975;50:1070-3.
7. Wakahara T. Effectiveness of S-Urso tablets against chronic liver diseases. Diagn Treat 1975;63:1070.
8. Miyaji K. Effect of ursodeoxycholic acid on liver function of chronic liver disease. Jpn J Clin Exp Med 1976;53:1395.
9. Yamanaka M. Study of curative effect of ursodeoxycholic acid for chronic hepatitis by double-blind trial. Diagn Treat 1976;64:2150.
10. Rubin RA, Kowalski TE, Khandelwal M, Malet PF. Ursodiol for hepatobiliary disorders. Ann Intern Med 1994;121: 207-18.
11. Queneau PE, Montet JC. Hepatoprotection by hydrophilic bile salts. J Hepatol 1994;21:260-8.
12. Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol 1994;29(suppl. 204): 1-15.
13. Schölmerich J, Becher MS, Schmidt K, Schubert R, Becher MS, Feldhaus S, et al. Influence of hydroxylation and conjugation of bile salts on their membrane-damaging properties. Studies on isolated hepatocytes and lipid membrane vesicules. Hepatology 1984;4:661-6.
14. Güldütuna S, Zimmer G, Imhof M, Bhatti S, You T, Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholic acid . Gastroenterology 1993;104:1736-44.
15. Quist RG, Ton-Hu HT, Lillienau J, Hofmann AF, Barett KE. Activation of mast cells by bile acids. Gastroenterology 1991; 101:446-56.
16. Stiehl A, Rudolph G, Raedsch R, Möller B, Hopff U, Lotterer E, et al. Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology 1990;12:492-7.
17. Roda A, Grigolo B, Pelliciari R, Natalini B. Structure-activity relationship studies on natural and synthetic bile acids analogs. Dig Dis Sci 1989;34 (suppl 12):24S-35S.
18. Palmer RH. Bile acids, liver injury and liver disease. Arch Intern Med 1972;130:606-17.
19. Galle PR, Theilmann L, Raedsch R, Otto G, Stiehl A. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology 1990;12:486-91.
20. Salvioli G, Lugli R, Pradelli JM. Effects of bile salts on membranes. In: Calandra S, Carulli N, Salvioli G, eds. Liver and lipid metabolism. New York: Elsevier, 1984:163-79.
21. Spivey JR, Bronk SF, Gores GJ. Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes. Role for ATP depletion and cytosolic free calcium. J Clin Invest 1993;92:17-24.
22. Krähenbuhl S, Krähenbuhl-Glauser S, Stucki J, Geht P, Reichen J. Stereological and functional analysis of liver mitochondria from rats with secondary biliary cirrhosis: impaired mitochondrial metabolism and increased mitochondrial content per hepatocyte. Hepatology 1992;15:1167-72.
23. Krähenbuhl S, Talos C, Fischer S, Reichen J. Toxicity of bile acids on the electron transport chain of isolated rat mitochondria. Hepatology 1994;19:471-9.
24. Krähenbuhl S, Stucki J, Reichen J. Reduced activity of electron transport chain in liver mitochondria isolated from rats with secondary biliary cirrhosis. Hepatology 1992;15: 1160-6.
25. Sokol RJ, Devereaux M, Khandwala R, O'Brien K. Evidence for involvement of oxygen free radicals in bile acid toxicity to isolated rat hepatocytes. Hepatology 1993;17:869-81.
26. Rosser BG, Gores GJ. Liver cell necrosis: cellular mechanisms and clinical implications. Gastroenterology 1995;108: 252-75.
27. Patel T, Bronk SF, Gores GJ. Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes. J Clin Invest 1994;94:2183-92.
28. Stiehl A. Pattern of bile acids in cholestasis. In: Gentilini P, Arias IM, McIntyre N, Rodès J, eds. Cholestasis. Amsterdam: Elsevier, 1994:231-7.
29. Ostrow JD. In vitro studies of bile salts. Hepatology 1994; 19:1538-9.
30. Setoguchi T, Higashi S, Tateno S, Yahiro K, Katsuki T. Epimerization of the four 3,7-dihydroxy bile acid epimers by human fecal microorganisms in anaerobic mixed cultures and in feces. J Lipid Res 1984;25:1246-56.
31. Hirano S, Masuda N, Oda H. In vitro transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal flora, with particular reference to the natural conversion between the two bile acids. J Lipid Res 1981;22:735-43.
32. Stiehl A, Raedsch R, Rudolph G. Ileal excretion of bile acids: comparison with biliary bile composition and effect of ursodeoxycholic acid treatment. Gastroenterology 1988;94:1201-6.
33. Wong MH, Oelkers P, Craddock AL, Dawson PA. Expression cloning and characterization of the hamster ileal sodium-dependent bile acid transporter. J Biol Chem 1994;269:1340-7.
34. Amselberg A, Boyapalli RR, Schteingart CD, Hofmann AF. Carrier mediated transport of conjugated bile acids in the guinea pig jejunum: a new mechanism for conjugated bile acid absorption (abstract). Gastroenterology 1994;106:A219.
35. Montagni M, Aldini R, Roda A, Polimeni C, Sipahi AM, Roda E. Jejunal and ileal bile acid transport (abstract). Gastroenterology 1993;104:A265.
36. Ewerth S, Angelin B, Einarsson K, Nilsell K, Björkhem I. Serum concentration of ursodeoxycholic acid in portal veinous and systemic venous blood of fasting humans as determined by isotope dilution-mass spectrometry. Gastroenterology 1985;88:126-33.
37. Paumgartner G. Serum bile acids. Physiological determinants and results in liver disease. J Hepatol 1986;2:291-8.
38. Carrubi F, Guicciardi ME, Concari M, Bozzoli M, Carulli N. Physico-chemical properties of bile salts determine their hepatoprotective or toxic effects (abstract). J Hepatol 1993; 18(suppl. 1):S103.
39. Heuman D, Scott Mills A, McCall J, Hylemon P, Pandak W, Vlahcevic Z. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes. Gastroenterology 1991;100:203-11.
40. Erlinger S, Poo JL, Jacquemin E, Dumont M, Feldmann G, Braillon A, et al. Protective effect of ursodeoxycholic acid on secondary biliary cirrhosis and ethinyl estradiol-induced cholestasis in the rat. In: Paumgartner G, Stiehl A, Gerok W, eds. Bile acids as therapeutic agents: from basic science to clinical practice. London: Kluwer, 1991;251-5.
41. Jacquemin E, Dumont M, Mallet A, Erlinger S. Ursodeoxycholic acid improves ethinyl estradiol-induced cholestasis in the rat. Eur J Clin Invest 1993;23:794-802.
42. Zhao XM, Montet JC. Effects of bile salt supplementation on biliary secretion in estrogen-treated rats. J Nutr Biochem 1990;1:420-5.
43. Poo JL, Feldmann G, Erlinger S, Braillon A, Gaudin C, Dumont M, et al. Ursodeoxycholic acid limits liver histologic alterations and portal hypertension induced by bile duct ligation in the rat. Gastroenterology 1992;102:1752-9.
44. Fisher S, Neubrand M, Paumgartner G. Biotransformation of orally administered ursodeoxycholic acid in man as observed in gallbladder bile, serum and urine. Eur J Clin Invest 1993; 23:28-36.
45. Beuers U, Spengler U, Zwiebel FM, Pauletski J, Fisher S, Paumgartner G. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and chronic cholestatic liver disease. Hepatology 1992:15:603-8.
46. Eusufzai S, Ericsson S, Cederlund T, Einarsson K, Angelin B. Effect of ursodeoxycholic acid treatment on ileal absorption of bile acids in man as determined by the SeHCAT test. Gut 1991;32:1044-8.
47. Mazzella G, Rizzo N, Salzetta A, Iampieri R, Bovicelli L, Roda E. Management of intrahepatic cholestasis in pregnancy. Lancet 1991;2:1594-5.
48. Batta AK, Arora R, Salen G, Tint GS, Eskreis D, Katz S. Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatographymass spectrometry: effect of ursodeoxycholic acid treatment. J Lipid Res 1989;30:1953-62.
49. Lillienau J, Crombie DL, Munoz J, Longmire-Cook SJ, Hagey LR, Hofmann AF. Negative feed-back regulation of the ileal bile acid transport system in rodents. Gastroenterology 1993;104:38-46.
50. Zimmermann H, Reichen J. Ursodeoxycholate has no beneficial effect on liver function or histology in biliary cirrhosis in the rat. J Hepatol 1992;16:355-9.
51. Watson KJR, Roufail S, Sotirelis N, Breen KJ, Desmond PV, Sawer WH. Ursodeoxycholic acid does not prevent functional, membrane biochemical or histological changes in the chronically bile duct ligated rat (abstract). Gastroenterology 1991; 100:A810.
52. Frezza EE, Gerunda GE, Plebani M, Galligioni A, Giacomini A, Neri D, et al. Effect of ursodeoxycholic acid administration on bile duct proliferation and cholestasis in bile duct ligated rats. Dig Dis Sci 1993;38:1291-6.
53. Marteau P, Chazouillères O, Myara A, Jian R, Rambaud JC, Poupon R. Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man. Hepatology 1990;12:1206-8.
54. Chazouillères O, Hanniche M, Marteau P, Jian R, Poupon R. Evidence that the ileal absorption of bile acids is not increased in patients with chronic cholestasis: HCAT test results and effect of ursodeoxycholic acid (abstract). Hepatology 1994;20:258A.
55. Stiehl A, Raedsch R, Rudolph G. Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids. Gastroenterology 1990;98:424-8.
56. Higgins JV, Paul JM, Dumaswala R, Heubi JE. Down regulation of taurocholate transport by ileal BBM liver BLM in biliary-diverted rats. Am J Physiol 267;30:G501-7.
57. Rodrigues CMP, Kren BT, Steer CJ, Setchell KDR. Increased liver tissue ursodeoxycholic acid concentration and reduced lithocholate formation in rats orally administered the taurine conjugate of UDCA compared with unconjugated UDCA (abstract). Gastroenterology 1995;108:A1156.
58. Bijleveld CMA, Vonk RJ, Kuipers F, Havinga R, Beverhof R, Koopman BJ, et al. Benign recurrent intrahepatic cholestasis: altered bile acid metabolism. Gastroenterology 1989;97:427-32.
59. Crosignani A, Podda M, Bertolini E, Battezzati PM, Zuin M, Setchell K. Failure of ursodeoxycholic acid to prevent cholestatic episode in a patient with benign recurrent intrahepatic cholestasis: a study of bile acid metabolism. Hepatology 1991;13:1076-83.
60. Frenkiel PG, Lee DW, Cohen H, Gilmore CJ, Resser K, Bonorris GG, et al. The effect of diet on bile acids kinetics and biliary lipid secretion in gallstone patients treated with ursodeoxycholic acid. Am J Clin Nutr 1986;43:239-50.
61. Rudolph G, Endele R, Senn M, Stiehl A. Effects of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis. Hepatology 1993;17:1028-32.
62. Mazella G, Parini P, Bazzoli F, Villanova N, Festi D, Aldini R, et al. Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis. Dig Dis Sci 1993;38:896-902.
63. Crosignani A, Podda M, Battezzati PM, Bertolini E, Zuin M, Watson D, et al. Changes in bile acids composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology 1991;14:1000-7.
64. Jazrawi RP, De Caestecker JS, Goggin PM, Britten AJ, Joseph AE, Maxwell JD, et al. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 1994;106:134-42.
65. Schölmerich J, Baumgartner U, Miyai K, Gerok W. Tauroursodeoxycholate prevents taurolithocholate-induced cholestasis and toxicity in rat liver. J Hepatol 1990;10:280-3.
66. Loria A, Myara A, Chazouillères O, Serfaty L, Masini JP, Poupon R. Evidence that ursodeoxycholic acid (UDCA) increases biliary excretion of cholic acid (CA) and chenodeoxycholic acid (CDCA) in man (abstract). Gastroenterology 1994;106:A935.
67. Poupon R, Chrétien Y, Parquet M, Rey C, Ballet F, Infante R. Hepatic transport of bile acids in the isolated perfused rat liver: structure-kinetics relationship. Biochem Pharmacol 1988;37:209-12.
68. Galan AI, Jimenez R, Munoz ME, Gonzalez J. Effects of ursodeoxycholate on maximal biliary secretion of bilirubin in the rat. Biochem Pharmacol 1990;39:1175-80.
69. Palma J, Reyes H, Ribalta J, Iglesias J, Gonsalez MC, Hernandez I, et al. Effects of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy. Hepatology 1992; 15:1043-7.
70. Dumont M, Uchman S, Erlinger S. Hypercholeresis induced by ursodeoxycholic acid and 7-ketolithocholic acid in the rat: possible role of bicarbonate transport. Gastroenterology 1980;79:82-9.
71. Erlinger S. Hypercholeretic bile acids: a clue to the mechanism? Hepatology 1990;11:888-90.
72. - and effect of Na+/H-exchange inhibitors. Am J Physiol 1989;254:G232-41.
73. Yoon YB, Hagey LR, Hofmann AF, Gurantz D, Michelotti EL, Steinbach JH. Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents. Gastroenterology 1986:90:837-52.
74. Strazzabosco M, Poci C, Spirli C, Sartori L, Knuth A, Crepaldi G. Effect of ursodeoxycholic acid on intracellular pH in a bile duct epithelium-like cell line. Hepatology 1994;19: 145-54.
75. Lamri Y, Erlinger S, Dumont M, Roda A, Feldman G. Immunoperoxidase localisation of ursodeoxycholic acid in rat biliary epithelial cell. Evidence for a cholehepatic circulation. Liver 1992;12:351-4.
76. Knyrim K, Vakil M, Pfab R, Classen M. The effects of intraduodenal bile acid administration on biliary secretion of ionised calcium and carbonate in man. Hepatology 1989; 10:134-42.
77. Colombo C, Castellani MR, Balistreri WF, Seregni E, Assaisso ML, Giunta A. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 1992;15:677-84.
78. Cotting J, Lentze MJ, Reichen J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut 1990;31: 918-21.
79. Setchell KDR, O'Connell NC, Bern E, Rodrigues C, Fitz Simmons S, Terrin M, et al. Markedly decreased biliary ursodeoxycholic acid (UDCA) enrichment with high dose UDCA in cystic fibrosis associated liver disease. Optimization of therapeutic dose (abstract). Hepatology 1994;20:262A.
80. Heuman D, Pandak W, Hylemon P, Vlahcevic Z. Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes. Hepatology 1991;14:920-6.
81. Kanai S, Kitani K. Glycoursodeoxycholate is as effective as tauroursodeoxycholate in preventing the taurocholate-induced cholestasis in the rat (abstract). Hepatology 1983;3:811.
82. Tanikawa K, Kawahara T, Kumashiro R, Yoshitake M. Effects of bile acids on the cultured hepatocytes and Kupffer cells (abstract). Hepatology 1986;6:779.
83. Queneau PE, Bertault-Pérès P, Mesdjian E, Durand A, Montet JC. Diminution of an acute cyclosporine A-induced cholestasis by tauroursodeoxycholate in the rat. Transplantation 1993;56:530-4.
84. Queneau PE, Montet AM, Guitaoui M, Bertault-Peres P, Montet JC. Ursodeoxycholic acid prevents chronically cyclosporin A-induced cholestasis without altering the drug concentration in blood. A study in the rat (abstract). Gastroenterology 1993;104:A976.
85. Bouchard G, Youssef IM, Tuchweber B. Influence of oral treatment with ursodeoxycholic and tauroursodeoxycholic acids on estrogen-induced cholestasis in rats: effects on bile formation and liver plasma membranes. Liver 1993;13:193-202.
86. Utili R, Tripodi MF, Adinolfi LE, Gaeta GB, Abernathy CO, Zimmerman HJ, et al. Estradiol-17b-D-glucuronide (E-17-G) cholestasis in perfused rat liver: fate of E-17-G and choleretic response to bile salts. Hepatology 1990;11:735-42.
87. Heuman D. Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology 1993;104:1865-70.
88. Heuman D, Bajaj R. Ursodeoxycholate conjugates protect against disruption of cholesterol rich membranes by bile salts. Gastroenterology 1994;106:1333-41.
89. Vadakekalam J, Gores GJ. Ursodeoxycholate cytoprotection against hepatocyte killing by hydrophobic bile salts cannot be explained solely by changes in the hydrophobicity index (abstract). Hepatology 1992;16:134A.
90. Ohiwa T, Katagiri K, Hishino M, Hayakawa T, Nakai T. Tauroursodeoxycholate and tauro-b-muricholate exert cytoprotection by reducing intrahepatic taurochenodeoxycholate content. Hepatology 1993;17:470-6.
91. Botla R, Spivey JR, Aguilar H, Bronk SF, Gores GJ. Ursodeoxycholate inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection. J Pharmacol Exp Ther 1995;272:930-8.
92. Krähenbuhl S, Fischer S, Talos C, Reichen J. Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: dose-response study in isolated rat liver mitochondria. Hepatology 1994;20:1595-601.
93. Kallinowski B, Theilmann L, Zimmerman R, Gams E, Kommerell B, Steihl A. Effective treatment of cyclosporine-induced cholestasis in heart transplanted patients treated with ursodeoxycholic acid. Transplantation 1991;51:1128-9.
94. Reshef R, Cohen I, Shiller M, Szvalb S, Loberant N. Does ursodeoxycholic acid have a place in the treatment of amiodarone-induced cholestasis? J Clin Gastroenterol 1994;18:177-8.
95. ++ mechanisms defective in cholestasis. J Clin Invest 1993;92:2984-93.
96. ++ activity in rat hepatocytes. Hepatology 1988;8:887-91.
97. 2+ influx initiates death of hepatocytes injured by activation of complement. Liver 1994;14:200-5.
98. Combettes L, Dumont M, Berthon B, Erlinger S, Claret M. Release of calcium from the endoplasmic reticulum by bile acids in rat liver cells. J Biol Chem 1988;263:2299-303.
99. 2+ in rat hepatocytes. Eur J Biochem 1990;190:619-23.
100. 2+ signals in isolated rat hepatocytes. Gastroenterology 1993;104:604-12.
101. 2+ release from permeabilized liver cells and liver microsomes. J Biol Chem 1989;264:157-67.
102. 2+ and activates phosphorylase A in isolated hepatocytes. Am J Physiol 1993;264:G243-51.
103. Calmus Y, Weill B, Poupon R. Expression hépatique des molécules du complexe majeur d'histocompatibilité. Gastroenterol Clin Biol 1991;15:110-9.
104. Hillaire S, Boucher E, Calmus Y, Gane P, Ballet F, Franco D, et al. Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes. Gastroenterology 1994;107:781-8.
105. 2-microglobulin distribution in primary biliary cirrhosis. J Hepatol 1986;2:73-80.
106. Beuers U, Spenger U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992;16:707-14.
107. Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990;11:12-5.
108. Calmus Y, Arvieux C, Gane P, Boucher E, Nordlinger B, Rouger P, et al. Cholestasis induces major histocompatibility complex class I expression in hepatocytes. Gastroenterology 1992;102:1371-7.
109. Calmus Y, Weill B, Ozier Y, Chéreau C, Houssin D, Poupon R. Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse. Gastroenterology 1992;103:617-21.
110. Bouscarel B, Gettys TW, Fromm H, Dubner H. Ursodeoxycholic acid inhibits glucagon-induced cAMP formation in hamster hepatocytes: a role for PKC. Am J Physiol 1995; 268:G300-10.
111. Töx U, Arnold JC, Otto G, Theilmann L, Kommerell B, Stiehl A. Differences in the effect of ursodeoxycholic acid and chenodeoxycholic acid on the expression of HLA-molecules on human primary hepatocytes (abstract). Hepatology 1993;18:176A.
112. Lo SK, Chapman RW, Dooley JS, Fleming KA. Aberrant HLA-DR expression by bile duct epithelium in primary sclerosing cholangitis is down-regulated by ursodeoxycholic acid (abstract). Gastroenterology 1993;104(suppl.):A111.
113. Allen PM. Antigen presentation and autoimmunity. Hepatology 1988;8:677-9.
114. Yoshikawa M, Tsujii T, Matsumura K, Yamao J, Matsumura Y, Kubo R, et al. Immunomodulatory effects of ursodeoxycholic acid immune responses. Hepatology 1992;16: 358-64.
115. Calmus Y, Podevin P, Robert A, Poupon R. Differential effects of chenodeoxycholic and ursodeoxycholic acids on expression of procoagulant activity by human monocytes. J Hepatology 1994;20:466-72 .
116. Lacaille F, Paradis K. The immunosuppressive effect of ursodeoxycholic acid: a comparative in vitro study on human peripheral blood mononuclear cells. Hepatology 1993;18: 165-72.
117. Castellanos AR, Bounds WE, Holcombe RF, Shiau YF. Effect of ursodeoxycholic acid on lymphocyte cytotoxic activity in mice (abstract). Gastroenterology 1993;104:A884.
118. Poupon RE, Balkau B, Eschwège E, Poupon R, UDCA-PBC Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991;324:1548-54.
119. Friman S, Persson H, Shersten T, Svanvik J, Karlberg I. Adjuvant treatment with ursodeoxycholic acid reduces acute rejection after liver transplantation. Transplant Proc 1992; 24:389-90 .
120. Fried R, Murakami C, Fisher L, Willson RA, Sullivan KM, McDonald GB. Ursodeoxycholic acid treatment for refractory chronic graft-versus-host disease of the liver. Ann Intern Med 1992;116:624-9.
121. Stiehl A, Raedsch R. Die Behandlung der primar sklerosierenden Cholangitis mit Ursodeoxycholsaur. Z Gastroenterologie 1989;24:136.
122. Chazouillères O, Poupon R, Capron JP, Metman EH, Dhumeaux D, Amouretti M, et ai. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 1990;11:120-3.
123. O'Brien CB, Senior JR, Arora-Mirchandani R, Batta AK, Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 1991;14:838-47.
124. Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994;20:57-64.
125. Kurihara T, Akimoto M, Abe K, Hashimoto H, Ishiguro H, Niimi A, et al. Inhibitory effect of ursodeoxycholic acid on the progression of chronic hepatic disorders with special reference to increases in blood flow. Clin Ther 1993;15:866-74.
126. Boucher E, Jouanolle H, André P, Ruffault A, Guyader D, Moirand R, et al. Interferon and ursodeoxycholic acid combined therapy in the treament of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. Hepatology 1995;21:322-7.
127. Takano S, Ito Y, Yokosuka O, Uchiumi K, Hirota K, Omata M. A multicenter randomized controlled study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994;20:558-64.
128. Plevris JN, Hayes PC, Bouchier IAD. Ursodeoxycholic acid in the treatment of alcoholic liver disease. Eur J Gastroenterol Hepatol 1991;3:653-6.
129. Fried RH, Murakami CS, Fisher LD, Willson RA, Sullivan KM, McDonald GB. Ursodeoxycholic acid treatment for refractory chronic graft-versus-host disease of the liver. Ann Intern Med 1992;116:624-9.
130. Zhao XM, Montet JC. Beta-muricholic acid: a new hepato-protective agent. J Nutr Biochem 1993;4:105-12.